The grant will enable GenVec to expand its existing contract with MVI to develop preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of those studies, GenVec, MVI, and the U.S. Agency for International Development will consider preclinical and clinical development of promising vaccine candidates.
GenVec, which began working with MVI in 2004, also receives funding from USAID. MVI was founded in 1999 with a $50 million grant from the Bill & Melinda Gates Foundation to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world.
"We appreciate the continued support from MVI and USAID," said Dr. Joseph Bruder, head of GenVec's malaria program. "And we look forward to advancing GenVec's vaccine technology through this collaboration."